SG/CALL/EDWARDS LIFESCIENCES/80/0.1/21.03.25 | Market Closed - Deutsche Boerse AG 01:12:59 04/07/2024 am IST | ||
| 1.84 EUR | -3.66% |
|
| Current month | -8.91% | ||
| 1 month | +2.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 1.84 | -3.66% |
| 02/24/02 | 1.91 | +1.60% |
| 01/24/01 | 1.88 | -6.93% |
| 28/24/28 | 2.02 | -4.27% |
| 27/24/27 | 2.11 | +6.57% |
Delayed Quote Deutsche Boerse AG
Last update July 04, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SU2MFA |
| ISIN | DE000SU2MFA3 |
| Date issued | 22/11/2023 |
| Strike | 80 $ |
| Maturity | 21/03/2025 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.7 € |
|---|---|
| Lowest since issue | 1.11 € |
| Spread | 0.1 € |
| Spread % | 5.15% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
91.08
USD
Average target price
96.13
USD
Spread / Average Target
+5.54%
- Stock Market
- Warrants
- Warrant
